et_companiesabout 12 hours ago
BEARISH(90%)
sell
Rising costs of key chemicals choke production at drug ingredient makers
Read original source+51.4
Market Impact Score
-100 Bearish+100 Bullish
AI Analysis
Raw material costs are a significant component of pharmaceutical manufacturing, and their surge can severely impact profitability and production.
Trading Insight
Bearish bias on API and bulk drug manufacturers; cautious on integrated pharma companies due to potential margin pressure.
Quick check: SUNPHARMA neutral (+0.3% 1d), CIPLA bearish bias (oversold).
Key Evidence
- •Bulk-drug manufacturers facing severe cost crisis due to surging prices of key solvents and intermediates.
- •Supply disruptions linked to West Asia conflict.
- •Led to production halts for several units.
- •Paracetamol API prices more than doubling.
- •Impacts entire pharmaceutical value chain.
Affected Stocks
SUNPHARMASun Pharmaceutical Industries
Negative
As a large pharmaceutical company, it relies on bulk drugs and APIs; rising costs could impact its manufacturing expenses and profitability.
Sectors:pharma
AI-powered analysis by
Anadi Algo News